AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

11,234.00p
   
  • Change Today:
    -182.00p
  • 52 Week High: 13,276.00
  • 52 Week Low: 9,725.00
  • Currency: UK Pounds
  • Shares Issued: 1,550.61m
  • Volume: 135,869
  • Market Cap: £174,195m
  • RiskGrade: 123

Regulatory News

Calquence recommended for EU approval in 1L MCL 31-Mar-2025 07:05 RNS
Imfinzi approved in the US for bladder cancer 31-Mar-2025 07:00 RNS
AZN invests $2.5bn in Beijing R&D & manufacturing 21-Mar-2025 10:58 RNS
Eneboparatide Phase III trial met primary endpoint 17-Mar-2025 07:10 RNS
Imfinzi approved in EU for limited-stage SCLC 17-Mar-2025 07:05 RNS
AstraZeneca to acquire EsoBiotec 17-Mar-2025 07:00 RNS
Holding(s) in Company 12-Mar-2025 18:00 RNS
Director/PDMR Shareholding 07-Mar-2025 15:00 RNS
Notice of AGM 07-Mar-2025 11:00 RNS
Imfinzi improved EFS in early-stage gastric cancer 07-Mar-2025 07:00 RNS
Director/PDMR Shareholding 06-Mar-2025 15:00 RNS
Director/PDMR Shareholding 05-Mar-2025 15:00 RNS
Total Voting Rights 03-Mar-2025 15:00 RNS
Imfinzi recommended for EU approval for AEGEAN 03-Mar-2025 07:00 RNS
Enhertu recommended in EU in post-ET breast cancer 28-Feb-2025 13:00 RNS
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 11,234.00p
Change Today -182.00p
% Change -1.59 %
52 Week High 13,276.00
52 Week Low 9,725.00
Volume 135,869
Shares Issued 1,550.61m
Market Cap £174,195m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.34% below the market average93.34% below the market average93.34% below the market average93.34% below the market average93.34% below the market average
87.23% below the sector average87.23% below the sector average87.23% below the sector average87.23% below the sector average87.23% below the sector average
Price Trend
41.51% above the market average41.51% above the market average41.51% above the market average41.51% above the market average41.51% above the market average
51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average51.02% above the sector average
Income
65.81% below the market average65.81% below the market average65.81% below the market average65.81% below the market average65.81% below the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Growth
85.34% above the market average85.34% above the market average85.34% above the market average85.34% above the market average85.34% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average

What The Brokers Say

Strong Buy 10
Buy 15
Neutral 4
Sell 0
Strong Sell 0
Total 29
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 20-Feb-25 08-Aug-24
Paid 24-Mar-25 09-Sep-24
Amount 210.00¢ 100.00¢

Trades for 31-Mar-2025

Time Volume / Share Price
11:50 40 @ 11,234.00p
11:49 45 @ 11,229.42p
11:49 45 @ 11,230.07p
11:49 6 @ 11,232.00p
11:49 35 @ 11,232.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page